Evidence map›Paper›PMID 40454077›Full record

ArticleACS omega2025

Production of a Recombinant Fibrinolytic Protease from an Isolate of Serratia marcescens from the Amazon Basin.

Thayana Cruz Souza, Marcos Gustavo Araujo Schwarz, Paloma Rezende Corrêa, Marília Alves Figueira Melo, Adolfo Jose Mota, Ormezinda Celeste Cristo Fernandes, Leila Mendonça-Lima, Wim Degrave

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thayana Cruz SouzaInstituto Leônidas e Maria Deane - ILMD, Fiocruz-Amazonas, Rua Teresina, 476, Adrianópolis, Manaus AM 69057-070, Brazil.
Marcos Gustavo Araujo SchwarzLaboratório de Biologia Molecular Aplicada à Micobactérias, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID https://orcid.org/0000-0002-6858-0860
Paloma Rezende CorrêaLaboratório de Biologia Molecular Aplicada à Micobactérias, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Marília Alves Figueira MeloLaboratório de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Adolfo Jose MotaLaboratório de Biodegradação, Universidade Federal do Amazonas, UFAM. Av. Rodrigo Octávio, 6200, Coroado I, Manaus AM 69080-900, Brazil.
Ormezinda Celeste Cristo FernandesInstituto Leônidas e Maria Deane - ILMD, Fiocruz-Amazonas, Rua Teresina, 476, Adrianópolis, Manaus AM 69057-070, Brazil.
Leila Mendonça-LimaLaboratório de Biologia Molecular Aplicada à Micobactérias, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Wim DegraveLaboratório de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous fibrinolytic agents are essential for the treatment of cardiovascular diseases, acting through plasminogen activation to dissolve thrombi. However, current therapies are often limited by low fibrin specificity, high production costs, and side effects such as bleeding and allergic reactions. In this study, we describe a novel fibrinolytic protease, rSM519, derived from Serratia marcescens CBAM 519 and recombinantly expressed in Escherichia coli. The enzyme was purified via affinity chromatography and exhibited a molecular mass of 56 kDa. Biochemical assays revealed that rSM519 is a metalloprotease with optimal activity at pH 9.0 and 37 °C, significantly enhanced by Mn

Identifiers

PMID40454077
PMCPMC12123961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.